Compare Stocks: JBIO, PBLS, TNGX, and DNLI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.73 +1.3%	$23.46	$12.58 ▼ $27.30	$3.88B	1.01	1.68 million shs	3.05 million shs
JBIO Jade Biosciences	$22.24 +2.5%	$19.67	$6.67 ▼ $28.00	$1.07B	1.49	923,391 shs	1.11 million shs
PBLS Parabilis Medicines	$35.58 +1.9%	$29.87	$24.51 ▼ $36.82	$4.12B	N/A	445,119 shs	263,693 shs
TNGX Tango Therapeutics	$29.00 +0.7%	$28.37	$6.25 ▼ $34.39	$4.16B	1.16	2.35 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+1.27%	+1.56%	-6.01%	+26.04%	+72.33%
JBIO Jade Biosciences	+2.49%	+11.20%	-0.94%	-13.83%	+184.04%
PBLS Parabilis Medicines	+1.95%	+10.22%	+17.23%	+3,557,999,900.00%	+3,557,999,900.00%
TNGX Tango Therapeutics	+0.73%	+5.19%	-3.72%	+25.98%	+346.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$24.73 +1.3%	$23.46	$12.58 ▼ $27.30	$3.88B	1.01	1.68 million shs	3.05 million shs
JBIO Jade Biosciences	$22.24 +2.5%	$19.67	$6.67 ▼ $28.00	$1.07B	1.49	923,391 shs	1.11 million shs
PBLS Parabilis Medicines	$35.58 +1.9%	$29.87	$24.51 ▼ $36.82	$4.12B	N/A	445,119 shs	263,693 shs
TNGX Tango Therapeutics	$29.00 +0.7%	$28.37	$6.25 ▼ $34.39	$4.16B	1.16	2.35 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+1.27%	+1.56%	-6.01%	+26.04%	+72.33%
JBIO Jade Biosciences	+2.49%	+11.20%	-0.94%	-13.83%	+184.04%
PBLS Parabilis Medicines	+1.95%	+10.22%	+17.23%	+3,557,999,900.00%	+3,557,999,900.00%
TNGX Tango Therapeutics	+0.73%	+5.19%	-3.72%	+25.98%	+346.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.17	42.20% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.57	131.89% Upside
PBLS Parabilis Medicines	3.00	Buy	$41.67	17.11% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$42.15	45.36% Upside

Current Analyst Ratings Breakdown

Latest JBIO, PBLS, TNGX, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $36.00
7/17/2026	DNLI Denali Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TNGX Tango Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $40.00
7/16/2026	DNLI Denali Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $35.00
7/15/2026	TNGX Tango Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$46.00
7/13/2026	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00
7/13/2026	DNLI Denali Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$29.00
7/7/2026	PBLS Parabilis Medicines	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/6/2026	PBLS Parabilis Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/6/2026	PBLS Parabilis Medicines	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	PBLS Parabilis Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	11.87	N/A	N/A	$6.91 per share	3.58
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	$62.38M	67.25	N/A	N/A	$2.57 per share	11.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$512.54M	-$2.88	N/A	N/A	N/A	N/A	-52.20%	-43.86%	N/A
JBIO Jade Biosciences	-$127.41M	-$2.02	N/A	N/A	N/A	N/A	-51.34%	-47.32%	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$101.59M	-$0.83	N/A	N/A	N/A	N/A	-41.54%	-33.44%	8/10/2026 (Estimated)

Latest JBIO, PBLS, TNGX, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	N/A	N/A	N/A	$1.56 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
5/13/2026	Q1 2026	TNGX Tango Therapeutics	-$0.32	-$0.32	N/A	-$0.32	$0.58 million	N/A
5/7/2026	Q1 2026	DNLI Denali Therapeutics	-$0.73	-$0.69	+$0.04	-$0.69	$2.57 million	N/A
5/7/2026	Q1 2026	JBIO Jade Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	0.01	9.28	9.28
JBIO Jade Biosciences	N/A	14.29	14.29
PBLS Parabilis Medicines	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	27.38	27.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
JBIO Jade Biosciences	N/A
PBLS Parabilis Medicines	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	9.70%
JBIO Jade Biosciences	23.06%
PBLS Parabilis Medicines	N/A
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	158.71 million	143.32 million	Optionable
JBIO Jade Biosciences	20	49.36 million	37.98 million	N/A
PBLS Parabilis Medicines	N/A	118.15 million	N/A	N/A
TNGX Tango Therapeutics	90	144.65 million	135.25 million	Optionable

JBIO, PBLS, TNGX, and DNLI Headlines

Recent News About These Companies

Tango Therapeutics Announces Executive Chair Transition

August 6 at 6:24 PM | globenewswire.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

August 3, 2026 | seekingalpha.com

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

August 3, 2026 | zacks.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts

August 3, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Analysts

August 3, 2026 | marketbeat.com

Perceptive Advisors LLC Has $16.91 Million Stock Holdings in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $6.29 Million Position in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Stempoint Capital LP Acquires Shares of 200,919 Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

ADAR1 Capital Management LLC Sells 90,021 Shares of Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

July 28, 2026 | marketbeat.com

Tango Therapeutics, Inc. $TNGX Shares Sold by Siren L.L.C.

July 24, 2026 | marketbeat.com

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

July 22, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX is Trv Gp Iv LLC's 2nd Largest Position

July 21, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 6.1% - Time to Buy?

July 17, 2026 | marketbeat.com

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

July 15, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Initiates Coverage on Tango Therapeutics (NASDAQ:TNGX)

July 15, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.7% - Here's What Happened

July 13, 2026 | marketbeat.com

Candriam S.C.A. Purchases 560,434 Shares of Tango Therapeutics, Inc. $TNGX

July 12, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Recommendation of "Moderate Buy" from Analysts

July 9, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 Shares of Stock

July 3, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, PBLS, TNGX, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$24.73 +0.31 (+1.27%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$25.02 +0.29 (+1.16%)

As of 04:50 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Jade Biosciences NASDAQ:JBIO

$22.24 +0.54 (+2.49%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$22.26 +0.03 (+0.11%)

As of 08/6/2026 04:10 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Parabilis Medicines NASDAQ:PBLS

$35.58 +0.68 (+1.95%)

As of 08/6/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Tango Therapeutics NASDAQ:TNGX

$29.00 +0.21 (+0.73%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$27.65 -1.35 (-4.64%)

As of 08/6/2026 06:45 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JBIO, PBLS, TNGX, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JBIO, PBLS, TNGX, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JBIO, PBLS, TNGX, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, PBLS, TNGX, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Jade Biosciences NASDAQ:JBIO

Parabilis Medicines NASDAQ:PBLS

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JBIO, PBLS, TNGX, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JBIO, PBLS, TNGX, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JBIO, PBLS, TNGX, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, PBLS, TNGX, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Jade Biosciences NASDAQ:JBIO

Parabilis Medicines NASDAQ:PBLS

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools